A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

Last updated:
2026-08-15
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

PHASE 2, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY AND EFFICACY STUDY OF CDR132L ON REVERSE CARDIAC REMODELLING IN PARTICIPANTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND LEFT VENTRICULAR HYPERTROPHY

Intervention/treatment:
CDR132L
Medical condition:
HEART FAILURE WITH PRESERVED EJECTION FRACTION
Protocol code:
NN6706-8212
Control number:
292740
Status:
Recruiting
Approved:
January 30, 2025
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT06979362
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
40 Years to 84 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Novo Nordisk
Role
CONTACT
Phone:
(+1) 866-867-7178
Sponsor
NOVO NORDISK CANADA INC

Locations

IUCPQ - Universite Laval
Québec, G1V 4G5
NOT_YET_RECRUITING

British Columbia

St Pauls Hospital
Vancouver, British Columbia, V6Z1Y6
COMPLETED

Ontario

Cardio Health Clinical Trials
Hamilton, Ontario, L8W 3K5
NOT_YET_RECRUITING
Cardio Health Clinical Trials
Mississauga, Ontario, L5M 2S6
RECRUITING
Hamilton General Hospital
Hamilton, Ontario, L8L 5G4
COMPLETED
Hamilton Hlth Sc. - General Site
Hamilton, Ontario, L8L 2X2
NOT_YET_RECRUITING
Premier Clinical Trial Research Network (PCTRN)
Hamilton, Ontario, L8L 5G4
NOT_YET_RECRUITING
St. Michael's Hospital
Toronto, Ontario, M5B 1W8
NOT_YET_RECRUITING
University of Ottawa Heart Institute (UOHI)
Ottawa, Ontario, K1Y 4W7
RECRUITING
William Osler Hel Bra Civic Hs
Brampton, Ontario, L6R 3J7
NOT_YET_RECRUITING
Winchester Dist Memorial Hosp
Winchester, Ontario, K0C 2K0
RECRUITING
Women's College Hospital
Toronto, Ontario, M5S 1B1
NOT_YET_RECRUITING
Did you find what you were looking for?